Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
P/B ratio for Relmada Therapeutics, Inc. (RLMD)
P/B ratio as of 2023: 1.46
According to Relmada Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.46. At the end of 2022 the company had a P/B ratio of 0.74.
P/B ratio history for Relmada Therapeutics, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.46 |
| 2022 | 0.74 |
| 2021 | 1.90 |
| 2020 | 4.74 |
| 2019 | 3.11 |
| 2018 | 6.04 |
| 2017 | -2.30 |
| 2016 | 6.78 |
| 2015 | 3.76 |
| 2014 | 11.45 |
| 2013 | -1.03 |
| 2012 | 7527.73 |